Interview John Soloninka, President & CEO, HTX, Canada
John Soloninka, President & CEO of HTX, talks about his vast experience in the pharmaceutical and healthcare sector, why he feels there is much room for growth in Canada still,…
We combine world-leading expertise in antibody generation and disease biology to create superior therapeutic antibodies. Our therapeutic antibody candidates are derived from a state-of-the-art phage display platform developed and refined by world-leading researchers at the University of Toronto, and we focus on developing novel functional modulators of key signalling pathways in cancer and fibrosis.
While most immuno-oncology products in the clinic target the immunosuppressive factors that help tumors evade an attack, Northern Biologics Inc.’s anti-LIF antibody takes a step further.
By simultaneously blocking both immunosuppression and self renewal of cancer stem cells the newco expects the antibody to be effective against a wider range of cancers than other immune oncology programs.
Contact:
Address: 101 College Street TMDT 11-301, Toronto, ON M5G 1L7 Canada
Tel.: +1 416-634-7132
Website: http://northernbiologics.com/
Email: info@northernbiologics.com
John Soloninka, President & CEO of HTX, talks about his vast experience in the pharmaceutical and healthcare sector, why he feels there is much room for growth in Canada still,…
Pierre Montanaro, President and CEO of Pharmetics, discusses the history of his company’s work in the private label business and future plans to expand into a wider variety of areas…
David Goodman, CEO of Pharmascience, describes the importance of balancing innovation with low cost products in Canada and outlines his company’s strategy for growth domestically and internationally. 2013 marks the…
John Soloninka, President & CEO of HTX, talks about his vast experience in the pharmaceutical and healthcare sector, why he feels there is much room for growth in Canada still,…
Pierre Montanaro, President and CEO of Pharmetics, discusses the history of his company’s work in the private label business and future plans to expand into a wider variety of areas…
Wendy Adams, General Manager of Galderma Canada, speaks about the importance of the Canadian market for the global company, what sets Galderma apart from its competitors, and where she sees…
Despite declining investments by big pharma in recent years, Canada has created a number of innovative ways to incentivize R&D throughout its vast geography. “Science powers commerce,” Canadian Prime Minister…
Deborah Brown, President of EMD Serono Canada, talks about Canada’s emerging market mentality, despite being a developed country, and how this lack of innovation and risk-taking could ultimately break Canada’s…
The president of Brancorth Medical talks about the challenges of the start-up med tech scene in Canada, turning innovation into corporate success, and the role of the government in creating…
Mr. Lebrun discusses the role that BIOQuébec plays in the industry, its aims in representing several sectors and their plans for the coming years. Could you introduce BIOQuébec and its…
The funding of Canada’s biotech industry has changed drastically in recent years. Peter Van Der Velden of Lumira Capital discusses those changes and how his venture capital business is adapting…
Riaz Bandali, President ESD of InVentiv Health Clinical discusses the ways in which the company’s unique combination of different technologies and capabilities will help lead the way to better healthcare…
See our Cookie Privacy Policy Here
